GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook

GSK plc (GSK) reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year on a reported basis and 10% at a constant exchange rate (CER) due to increased operating expenses during the quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Quarterly revenues rose 1% on a reported basis and 4% at CER to $10.4 billion (£8.12 billion). The top line outpaced the Zacks ...